Aurobindo Pharma Ltd
- All
- News
- Videos
-
Aurobindo Pharma Shares Jump 6% After Drug Maker Announces $900-Million US Acquisition
Aurobindo Pharma share price jumped more than 6 per cent in intraday trade with large volumes after the announcement. Aurobindo Pharma said it will acquire the dermatology and oral solids businesses from Sandoz Inc, USA, a unit of Swiss pharmaceutical company Novartis. Aurobindo Pharma said the deal worth $900 million was expected to close in 2019...
-
Aurobindo Pharma Buys Parts Of Sandoz US From Novartis For $900 Million
Novartis AG said on Thursday it would sell the dermatology and generic US oral solids portfolios of Sandoz US to Aurobindo Pharma Ltd for $900 million, as the Swiss drug maker looks to focus on higher growth areas. The deal also includes about 300 products and additional development projects of Sandoz and an additional $100 million in performance...
-
Sensex, Nifty End On A Flat Note, BEML Surges 16%
Software bellwether Tata Consultancy Services Ltd is due to report results on Thursday, while rival Infosys Ltd will do so on Friday.
-
Aurobindo Pharma Shares Hit 9-Month Low On US Price Fixing Lawsuit
The lawsuit, filed in the US District Court for the District of Connecticut by 20 US states, also named Heritage Pharmaceuticals Inc, a company owned by Emcure Pharma Ltd, as a "ring leader" of the price manipulation.
-
Buy Ceat, Aurobindo Pharma; Accumulate Sun Pharma: Sumeet Bagadia
Fresh longs in Nifty should be created only if it moves above 8,550 and if it breaks below 8,480 on the downside, it can fall to 8,400 levels, says Sumeet Bagadia, associate director at Choice Broking.
-
Buy Reliance Infra, Aurobindo Pharma; Avoid Ashok Leyland: Sumeet Bagadia
Nifty faces resistance around levels of 8,400 and till the time 8,400 is not taken out, Nifty can see a correction up to levels of 8,300-8,280, says Sumeet Bagadia, associate director at Choice Broking. Correction should be used as a buying opportunity in Nifty with stop loss around 8,270-8,280 for target of 8,400, added Mr Bagadia.
-
Aurobindo Pharma Fourth Quarter Profit Jumps 40%; Shares Rise 4%
Aurobindo Pharma Ltd, India's fourth-largest drugmaker by sales, said higher sales in the United States and emerging markets helped its fourth-quarter net profit grow 40 per cent, above estimates, sending shares up as much as 4 per cent.
-
Cabinet To Decide On Axis Bank Rs 12,973 Crore Foreign Investment Proposal
The Cabinet Committee on Economic Affairs will take a final call on Axis Bank's Rs 12,973-crore foreign investment proposal, the Finance Ministry said on Wednesday.
-
Finance Ministry Looks To Expedite Clearances To FDI Proposals
Stressing that fast clearances and automatic process are key to recent surge in FDI inflows, Economic Affairs Secretary Shaktikanta Das on Thursday said all FDI applications received up to March 15 are listed in agenda for the next meeting of Foreign Investment Promotion Board (FIPB).
-
NSE to Add Eicher Motors, 3 Others to Nifty
The National Stock Exchange (NSE) said it would add Aurobindo Pharma Ltd, Bharti Infratel Ltd, Eicher Motors Ltd, and Tata Motors' Differential Voting Rights to its benchmark Nifty 50 index.
-
Aurobindo Pharma Gets US FDA Nod for Acid Reflux Treatment Drug
Aurobindo Pharma Ltd today said it has received final approval from the US health regulator to manufacture and market Famotidine Tablets used for acid reflux treatment.
-
Aurobindo Pharma Q1 Net Up 4% at Rs 432 Cr
Aurobindo Pharma on Wednesday reported a 4.1 per cent increase in net profit at Rs 432.4 crore for the fiscal first quarter that ended on June 30, 2015.
-
Aurobindo Pharma Earmarks Rs 900 Crore Capex for FY16
Elaborating on the capital expenditure plans during the current fiscal, he said the company is continuing to invest in enhancing finished dosage as well as active pharmaceutical ingredient (API) capacity.
-
Aurobindo Pharma Gets USFDA Nod for Sildenafil Injection
The company has received approval from the US Food and Drug Administration (USFDA) to manufacture and market Sildenafil injection in the US market, Aurobindo Pharma Ltd said in a statement.
-
Aurobindo to Pharma Buy US Nutritional Supplements Maker for $133 Million
Aurobindo said the deal with Chatsworth, California-based Natrol, which sells vitamins and supplements as well as diet and weight management products, will help the company expand its over-the-counter products business in the United States.
-
Aurobindo Pharma Shares Jump 6% After Drug Maker Announces $900-Million US Acquisition
Aurobindo Pharma share price jumped more than 6 per cent in intraday trade with large volumes after the announcement. Aurobindo Pharma said it will acquire the dermatology and oral solids businesses from Sandoz Inc, USA, a unit of Swiss pharmaceutical company Novartis. Aurobindo Pharma said the deal worth $900 million was expected to close in 2019...
-
Aurobindo Pharma Buys Parts Of Sandoz US From Novartis For $900 Million
Novartis AG said on Thursday it would sell the dermatology and generic US oral solids portfolios of Sandoz US to Aurobindo Pharma Ltd for $900 million, as the Swiss drug maker looks to focus on higher growth areas. The deal also includes about 300 products and additional development projects of Sandoz and an additional $100 million in performance...
-
Sensex, Nifty End On A Flat Note, BEML Surges 16%
Software bellwether Tata Consultancy Services Ltd is due to report results on Thursday, while rival Infosys Ltd will do so on Friday.
-
Aurobindo Pharma Shares Hit 9-Month Low On US Price Fixing Lawsuit
The lawsuit, filed in the US District Court for the District of Connecticut by 20 US states, also named Heritage Pharmaceuticals Inc, a company owned by Emcure Pharma Ltd, as a "ring leader" of the price manipulation.
-
Buy Ceat, Aurobindo Pharma; Accumulate Sun Pharma: Sumeet Bagadia
Fresh longs in Nifty should be created only if it moves above 8,550 and if it breaks below 8,480 on the downside, it can fall to 8,400 levels, says Sumeet Bagadia, associate director at Choice Broking.
-
Buy Reliance Infra, Aurobindo Pharma; Avoid Ashok Leyland: Sumeet Bagadia
Nifty faces resistance around levels of 8,400 and till the time 8,400 is not taken out, Nifty can see a correction up to levels of 8,300-8,280, says Sumeet Bagadia, associate director at Choice Broking. Correction should be used as a buying opportunity in Nifty with stop loss around 8,270-8,280 for target of 8,400, added Mr Bagadia.
-
Aurobindo Pharma Fourth Quarter Profit Jumps 40%; Shares Rise 4%
Aurobindo Pharma Ltd, India's fourth-largest drugmaker by sales, said higher sales in the United States and emerging markets helped its fourth-quarter net profit grow 40 per cent, above estimates, sending shares up as much as 4 per cent.
-
Cabinet To Decide On Axis Bank Rs 12,973 Crore Foreign Investment Proposal
The Cabinet Committee on Economic Affairs will take a final call on Axis Bank's Rs 12,973-crore foreign investment proposal, the Finance Ministry said on Wednesday.
-
Finance Ministry Looks To Expedite Clearances To FDI Proposals
Stressing that fast clearances and automatic process are key to recent surge in FDI inflows, Economic Affairs Secretary Shaktikanta Das on Thursday said all FDI applications received up to March 15 are listed in agenda for the next meeting of Foreign Investment Promotion Board (FIPB).
-
NSE to Add Eicher Motors, 3 Others to Nifty
The National Stock Exchange (NSE) said it would add Aurobindo Pharma Ltd, Bharti Infratel Ltd, Eicher Motors Ltd, and Tata Motors' Differential Voting Rights to its benchmark Nifty 50 index.
-
Aurobindo Pharma Gets US FDA Nod for Acid Reflux Treatment Drug
Aurobindo Pharma Ltd today said it has received final approval from the US health regulator to manufacture and market Famotidine Tablets used for acid reflux treatment.
-
Aurobindo Pharma Q1 Net Up 4% at Rs 432 Cr
Aurobindo Pharma on Wednesday reported a 4.1 per cent increase in net profit at Rs 432.4 crore for the fiscal first quarter that ended on June 30, 2015.
-
Aurobindo Pharma Earmarks Rs 900 Crore Capex for FY16
Elaborating on the capital expenditure plans during the current fiscal, he said the company is continuing to invest in enhancing finished dosage as well as active pharmaceutical ingredient (API) capacity.
-
Aurobindo Pharma Gets USFDA Nod for Sildenafil Injection
The company has received approval from the US Food and Drug Administration (USFDA) to manufacture and market Sildenafil injection in the US market, Aurobindo Pharma Ltd said in a statement.
-
Aurobindo to Pharma Buy US Nutritional Supplements Maker for $133 Million
Aurobindo said the deal with Chatsworth, California-based Natrol, which sells vitamins and supplements as well as diet and weight management products, will help the company expand its over-the-counter products business in the United States.
